Search
Telapristone acetate
go.drugbank.com/drugs/DB05253InvestigationalTelapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.
Pucotenlimab
go.drugbank.com/drugs/DB17552ApprovedInvestigationalIt received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.
Nirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalDesmoid tumors are typically characterized by aberrant activation in Notch signaling. … It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase
Coumaphos
go.drugbank.com/drugs/DB11390ExperimentalVet approvedIt is non-volatile in nature and is well known by a variety of names as such a _dip_ or _wash_. Coumaphos is widely used for both farm and domestic animals to control ticks, mites, flies and fleas.
Categories: Compounds used in a research, industrial, or household settingVT-111
go.drugbank.com/drugs/DB05646InvestigationalVT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.
HZT-501
go.drugbank.com/drugs/DB05369InvestigationalIt has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers.
Isometheptene
go.drugbank.com/drugs/DB06706ApprovedIsometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.
Barnidipine
go.drugbank.com/drugs/DB09227Investigationalafter a 1-year and 2-year follow-up period in 91% of the patients who had an initial response to the drug [A7842]. … It is available in modified-release oral tablets under the brand name Vasexten to be taken once daily in the morning.
ALGRX 1207
go.drugbank.com/drugs/DB06482ExperimentalALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.